Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announces it has entered into a definitive merger agreement (the “Merger Agreement”) with Pharma Two B Ltd., a late-clinical stage private Israeli company that is developing P2B001, an innovative combination product candidate in development for the treatment of Parkinson’s Disease (“PD”). Under the Merger Agreement, Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B (the “Merger”).
Read the full article: Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc //
Source: https://www.globenewswire.com/news-release/2024/07/22/2916500/0/en/Pharma-Two-B-Announces-Plans-to-Go-Public-via-Merger-with-Hepion-Pharmaceuticals-Inc-and-Concurrent-11-5-Million-Private-Placement.html